Fundz

Adial Pharmaceuticals acquires Azora Therapeutics

PUBLIC · ADILJun 11, 2026

Acquiring Company

Adial Pharmaceuticals

Acquired Company

Azora Therapeutics

Glen AllenEncinoBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalHealthcare

Description

Adial Pharmaceuticals has successfully acquired Azora Therapeutics, which brings a promising asset into its pipeline. The acquisition involves a concurrent private placement aiming to raise up to $64 million to support clinical development of Azora’s AT177 therapy. This strategic move positions Adial to enhance its capabilities in treating ulcerative colitis. The combined company is well-prepared to advance key clinical milestones.

Company Information

Company

Adial Pharmaceuticals

Location

Glen Allen, Virginia, United States

About

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company's ONWARDTM pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company's companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.

Fundz sees it the moment Adial Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Cary
Senior decision-maker at this company
••••••••@••••••••

See Cary's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Adial Pharmaceuticals's next move

Learn about Strategic plan

Frequently asked

Who acquired Azora Therapeutics?

Azora Therapeutics was acquired by Adial Pharmaceuticals, based in Glen Allen. The deal was reported on June 11, 2026. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. Adial Pharmaceuticals is publicly traded (ADIL) and operates in Biotechnology.

When did Adial Pharmaceuticals acquire Azora Therapeutics?

Adial Pharmaceuticals's acquisition of Azora Therapeutics was reported on June 11, 2026. Adial Pharmaceuticals has successfully acquired Azora Therapeutics, which brings a promising asset into its pipeline. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Azora Therapeutics do?

Azora is clinical stage pharmaceutical company developing novel therapies for serious inflammatory diseases like hidradenitis suppurativa (HS) and ulcerative colitis (UC). It is privately held, operating in Healthcare, and is based in Encino.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.